TMEM168

Across TCGA pan-cancer cohorts, TMEM168 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM168 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TMEM168 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM168 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

LSCC, COAD, and CCRCC are the cancer types where TMEM168 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.791	0.961	.003	38	view →
COAD	DFS	Tertile	All	1.000	0.820	.032	24	view →
CCRCC	OS	Median	All	0.742	1.000	.033	9	view →
PDAC	OS	Quartile	II,III,IV	0.608	0.388	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM168–LSCC (OS)

Open the LSCC breakdown →